Data collection

Motive is reborn following carve-out of Nokia’s device and service management businesses

Retrieved on: 
Monday, April 8, 2024
Automation, City centre, Growth, Internet of things, ESIM, Transport, City, Data collection, CPE, IMPACT, Online shopping

With more than a hundred top-tier customers worldwide, hundreds of thousands of device models recognized, and billions of endpoints under administration, Motive uniquely has the scale, expertise, and experience required to lead the device and service management market.

Key Points: 
  • With more than a hundred top-tier customers worldwide, hundreds of thousands of device models recognized, and billions of endpoints under administration, Motive uniquely has the scale, expertise, and experience required to lead the device and service management market.
  • The potential for growth in the device and service management market remains substantial, with emergent opportunities in smart cities, smart utilities, asset management, transportation, and industrial applications, as well as business-to-consumer services.
  • David Sharpley, CEO at Motive, said: “We are proud to announce the rebirth and reinvigoration of the Motive brand, with a focus on innovating in growth areas within the device and service management industry.
  • Device and service management activities across the full device landscape can be orchestrated from one comprehensive solution, delivering both savings and revenue generation opportunities to users of the Motive platform.

Leash Biosciences Announces $9.3 Million Seed Financing to Pioneer AI-Driven Medicinal Chemistry

Retrieved on: 
Friday, April 5, 2024
Drug design, Biotechnology, Drug discovery, Artificial intelligence, Stripe, Myriad Genetics, Protein folding, Biology, Data collection, Chemistry, Therapy, Machine learning, Data, Leash, Collection

SALT LAKE CITY, April 05, 2024 (GLOBE NEWSWIRE) -- Leash Biosciences, an artificial intelligence and machine learning (AI/ML)-native biotechnology company unleashing machine learning to solve medicinal chemistry, today announced the completion of a $9.3 million seed financing round to advance its mission of revolutionizing medicinal chemistry through modern computational methods and massive biological data collection. The oversubscribed round was led by Springtide Ventures with participation from MetaPlanet, Top Harvest Capital, Mitsui Global Investment, MFV Partners, Recursion CEO and co-founder Chris Gibson, and Recursion co-founder Blake Borgeson.

Key Points: 
  • SALT LAKE CITY, April 05, 2024 (GLOBE NEWSWIRE) -- Leash Biosciences, an artificial intelligence and machine learning (AI/ML)-native biotechnology company unleashing machine learning to solve medicinal chemistry, today announced the completion of a $9.3 million seed financing round to advance its mission of revolutionizing medicinal chemistry through modern computational methods and massive biological data collection.
  • To achieve this, Leash is producing bespoke, expansive datasets of protein targets binding to chemicals.
  • We believe a similar strategy will revolutionize how we approach medicinal chemistry," said Ian Quigley, CEO of Leash Biosciences.
  • "Leash's platform stands apart with its combined excellence in machine learning, experimental biology, and medicinal chemistry," said Claire Smith, Lead Investor at Springtide Ventures.

ByteTrade Lab and UC Berkeley Partner to Explore the Next Generation of Decentralized AI

Retrieved on: 
Wednesday, April 3, 2024
Personality, Learning, Partnership, FHL, Research, University, AI, Data collection, Shashank, Privacy, Artificial intelligence, Teaching

San Francisco, California, April 03, 2024 (GLOBE NEWSWIRE) -- ByteTrade Lab , an industrial partner with the University of California, Berkeley (“Berkeley”) FHL Vive Center, today announced that the partnership has led to the launch of GaiaNet , a new decentralized AI infrastructure project.

Key Points: 
  • San Francisco, California, April 03, 2024 (GLOBE NEWSWIRE) -- ByteTrade Lab , an industrial partner with the University of California, Berkeley (“Berkeley”) FHL Vive Center, today announced that the partnership has led to the launch of GaiaNet , a new decentralized AI infrastructure project.
  • GaiaNet is a decentralized network that provides secure, censorship-resistant, and monetizable AI agents that incorporate each individual’s proprietary knowledge and skills while preserving privacy.
  • “I am honored to collaborate with Berkeley in our shared mission to revolutionize learning through decentralized AI.
  • As an esteemed academic institution, UC Berkeley Vive Center is primed to leverage its expertise to openly support the advancement of decentralized AI, especially with its partner ByteTrade to explore the technologies behind GaiaNet.

Illegal Surveillance In Americans Homes & Devices Immediate Oversight Of Clearview AI & Similar Technologies Demanded By The McWhorter Foundation

Retrieved on: 
Wednesday, April 3, 2024
Freedom, Private, Trust, Internet of things, PALM, CK, Fourth Amendment, Law enforcement, Internet, Clearview AI, Impact, Privacy, Computer, Motorola Solutions, Weapon, Economic methodology, Data collection, Justice, Supreme court, Community engagement, Safety, Habit, Brennan Center for Justice, Family, Facial recognition

These technologies can capture detailed and intimate information about our private lives​ ( Brookings )​​ ( Brennan Center for Justice )​.

Key Points: 
  • These technologies can capture detailed and intimate information about our private lives​ ( Brookings )​​ ( Brennan Center for Justice )​.
  • The use of surveillance technology, including data monitoring and facial recognition, by law enforcement has significantly expanded, raising important questions about privacy, especially within private settings.
  • Independent Oversight and Regulation: We demand the establishment of rigorous oversight mechanisms, including independent bodies that involve community representatives to oversee the deployment and use of surveillance technologies.
  • McWhorter Foundation has not registered with the U.S. Securities and Exchange Commission (SEC) and may operate under exemptions.

YPrime Survey Reveals Challenges and Opportunities for Streamlining Oncology Trials with eCOA

Retrieved on: 
Wednesday, April 3, 2024
Risk, American Opportunity Tax Credit, Pros, Patient, Uncertainty, Burden, Pressure, Data collection, Clinical trial, Medical imaging

The report detailing and analyzing the findings, Decreasing the Burden of Oncology Clinical Trials with eCOA , sheds light on the specific challenges and opportunities surrounding electronic clinical outcome assessment (eCOA) use in oncology trials.

Key Points: 
  • The report detailing and analyzing the findings, Decreasing the Burden of Oncology Clinical Trials with eCOA , sheds light on the specific challenges and opportunities surrounding electronic clinical outcome assessment (eCOA) use in oncology trials.
  • While all clinical trials share similarities, oncology trials present distinct complexities.
  • "By improving patient engagement, streamlining data collection, and enabling real-time insights, eCOA platforms can significantly reduce risk and uncertainty in oncology trials.
  • For a complete analysis of the survey findings and a deeper dive into how eCOA can optimize your oncology trials, download the complimentary report, Decreasing the Burden of Oncology Clinical Trials with eCOA .

Ocean Power Technologies Announces “Merrows”: A Consolidated Solution for Maritime Domain Awareness

Retrieved on: 
Tuesday, April 2, 2024
Control, Machine learning, Cyber, OPT, MDA, Data analysis, Maritime domain awareness, Communication, Computer, PB, Data collection, Command, Collection, Ocean Power Technologies, Artificial intelligence

Merrows will be OPT’s groundbreaking consolidated solution offering comprehensive ocean surveillance.

Key Points: 
  • Merrows will be OPT’s groundbreaking consolidated solution offering comprehensive ocean surveillance.
  • Maritime Domain Awareness represents a complex challenge that encompasses the collection and transmission of data relating to all aspects of, on, under, adjacent to, or bordering on a sea, ocean, or other navigable waterway.
  • Ocean security is national security, and through Merrows, OPT is dedicated to providing the technologies and insights necessary to secure our maritime domains.
  • For more information about Ocean Power Technologies, visit www.OceanPowerTechnologies.com .

Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract

Retrieved on: 
Tuesday, April 2, 2024
Psilocybin, Psilocybe, Organization, Documentation, Learning, Certificate, Patient, Research, Good manufacturing practice, FRA, COA, International Council, Health Canada, GMP, Data collection, Quality, Harmonization, Ground substance, GACP, Water, Safety, ICH, MDMA, Good

Additionally, the Company has successfully completed the in-house encapsulation of psilocybin drug candidates in 5mg and 10mg dosage formats.

Key Points: 
  • Additionally, the Company has successfully completed the in-house encapsulation of psilocybin drug candidates in 5mg and 10mg dosage formats.
  • The third-party COA confirms critical information regarding potency, water content, microbial content, and heavy metal content, ensuring that the Natural Psilocybin Extract meets the predetermined specifications.
  • The completion of both extract validation and finished product testing aligns with Optimi's goal of advancing the drug candidate, marking significant progress toward its eventual release for human consumption.
  • “Obtaining successful results on the validation batches of psilocybin extract speaks to Optimi’s dedication to developing a repeatable, quality focused manufacturing process.

Ocean Power Technologies to Present at the AI & Technology Hybrid Investor Conference Presented by Water Tower Research on April 10

Retrieved on: 
Monday, April 1, 2024
Environmental monitoring, Conference, OPT, CFO, AI, NPS, Data collection, AT&T, Ocean Power Technologies, Renewable energy

This will be a live, interactive online event where investors are invited to ask questions in real time.

Key Points: 
  • This will be a live, interactive online event where investors are invited to ask questions in real time.
  • To learn more about the event, click this link: AI & Technology Hybrid Investor Conference Presented by Water Tower Research .
  • This deployment signifies the first installation of AT&T cellular technology on one of OPT's commercially proven ocean buoys.
  • These orders underscore the growing demand for OPT's advanced marine technologies and their applications in maritime surveillance, environmental monitoring, and ocean data collection.

BCA Labs Unveils AI-Powered BCA Protocol to Reshape AI Training Data, Puts Users in Control

Retrieved on: 
Thursday, March 28, 2024
Cloud, OpenAI, Growth, Intelligence, Internet, Social media, Artificial intelligence, BCA, AI, ZK, Data collection, Blockchain, OCAM, Privacy, NVIDIA, Cryptocurrency

BCA Labs received grants from Google and is part of the NVIDIA inception program.

Key Points: 
  • BCA Labs received grants from Google and is part of the NVIDIA inception program.
  • The recent stealth funding round, which astonishingly concluded in just three minutes, highlights the immense confidence and excitement surrounding the BCA Protocol.
  • Additionally, BCA Labs is fully integrating OpenAI into the BCA Protocol to harness the power of advanced artificial intelligence.
  • “The BCA Protocol harnesses the power of AI to create a fairer, more transparent data collection for training LLMs," said a representative of BCA Labs.

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, March 26, 2024
Research, Consultant, Administration, Patient, Breast, Prostate, Insurance, IND, Data collection, Investment, Interim, Therapy, Research and development, FDA, NK, Pharmaceutical industry

Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $1.36 million compared to $2.84 million for the same quarter of 2022.

Key Points: 
  • Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $1.36 million compared to $2.84 million for the same quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2023 were $1.81 million compared to $2.94 million for the same quarter in 2022.
  • Other income net of other expenses, for the fourth quarter ended December 31, 2023 was $0.21 million compared to $0.19 million for the same quarter ended December 31, 2022.
  • Net Loss: The Company reported a net loss of $2.96 million for the fourth quarter ended December 31, 2023 compared to a loss of $5.58 million for the same quarter in 2022.